Peripheral Neuropathy and cannabis in Missouri
The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.
- ✓ Yes
- LEGAL
- Up to 4 oz per 30-day s…
- POSSESSION
- $25/yr
- STATE FEE
- 3–21 d
- TIMELINE
Missouri statute and program
The Missouri Medical Marijuana Program is the operating authority for Missouri patient certification. The authoritative legal text is: Missouri Constitution Article XIV: Cannabis (Amendments 2 + 3).
What the evidence says about cannabis and Peripheral Neuropathy
Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Peripheral Neuropathy page.
How to qualify in Missouri
The Missouri Medical Marijuana Program requires the following registration steps for a Peripheral Neuropathy patient (or any qualifying diagnosis):
- Get a physician certification from a Missouri-licensed physician. Under Missouri Constitution Article XIV (Amendment 2 of 2018, expanded by Amendment 3 of 2022), any Missouri-licensed physician, advanced practice registered nurse, or physician assistant authorized to prescribe controlled substances may certify a patient. Missouri uses a broad practitioner-discretion standard: the practitioner certifies that, in their professional judgment, the patient may benefit from medical use of marijuana — no enumerated condition list applies.
- Apply through the Division of Cannabis Regulation patient portal. The patient creates an account in the Missouri Department of Health and Senior Services (DHSS) Division of Cannabis Regulation (DCR) patient portal, uploads the physician certification, a Missouri driver license or state ID, a passport-style photograph, and proof of Missouri residency. Caregivers register separately and undergo a state background check.
- Pay the $25 state registration fee. The annual Missouri medical marijuana patient ID card fee is $25 (reduced from $100 under 2023 DCR rules). Patients with a documented terminal illness pay no fee. Caregivers are $25 per caregiver. Fees are paid online during the DCR portal application.
- Receive the card and purchase from a Missouri dispensary. Missouri medical marijuana patient ID cards are issued within roughly 30 days of complete application (typically faster — many patients receive cards within 5 to 7 business days). With the card, patients may purchase up to 6 ounces over a 30-day rolling period from any of the licensed Missouri medical dispensaries. Adult-use retail also operates statewide for adults 21+; medical patients retain lower 4% medical excise tax versus the 6% adult-use rate, plus statutory employment protections.
- State registration fee
- $25
- Physician visit (typical)
- $125–$250
- Certification to card
- 3–21 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Missouri registration steps, fees, and reciprocity rules, see the Missouri cannabis-laws page.
ICD-10 code
A certifying physician documenting Peripheral Neuropathy for the Missouri medical cannabis program will typically record ICD-10 G62.9 or SNOMED-CT 42658009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Missouri list Peripheral Neuropathy as a qualifying condition for medical cannabis?
Yes. Missouri explicitly lists Peripheral Neuropathy as a qualifying condition under Missouri Medical Marijuana Program. A patient with a documented Peripheral Neuropathy diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Missouri rules.
How do I get a Missouri medical marijuana card for Peripheral Neuropathy?
Step one is finding a physician licensed in Missouri who is registered with Missouri Medical Marijuana Program and willing to evaluate Peripheral Neuropathy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Missouri does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.
What does the evidence say about cannabis for Peripheral Neuropathy?
For Peripheral Neuropathy, evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Peripheral Neuropathy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Peripheral Neuropathy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Peripheral Neuropathy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Peripheral Neuropathy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Missouri Constitution Article XIV: Cannabis (Amendments 2 + 3)accessed May 15, 2026
- Missouri Department of Health and Senior Services: Division of Cannabis Regulationaccessed May 15, 2026
- NORML: Missouri Lawsaccessed May 15, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 16, 2026
“Substantial evidence that cannabis is an effective treatment for chronic pain in adults.”
- NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026